254 related articles for article (PubMed ID: 30723117)
1. EZH2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis.
Zhao Y; Ding L; Wang D; Ye Z; He Y; Ma L; Zhu R; Pan Y; Wu Q; Pang K; Hou X; Weroha SJ; Han C; Coleman R; Coleman I; Karnes RJ; Zhang J; Nelson PS; Wang L; Huang H
EMBO J; 2019 Mar; 38(5):. PubMed ID: 30723117
[TBL] [Abstract][Full Text] [Related]
2. The EZH2-PHACTR2-AS1-Ribosome Axis induces Genomic Instability and Promotes Growth and Metastasis in Breast Cancer.
Chu W; Zhang X; Qi L; Fu Y; Wang P; Zhao W; Du J; Zhang J; Zhan J; Wang Y; Zhu WG; Yu Y; Zhang H
Cancer Res; 2020 Jul; 80(13):2737-2750. PubMed ID: 32312833
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer.
Wu C; Jin X; Yang J; Yang Y; He Y; Ding L; Pan Y; Chen S; Jiang J; Huang H
Oncotarget; 2016 Jan; 7(3):3440-52. PubMed ID: 26657505
[TBL] [Abstract][Full Text] [Related]
4. Involvement of EZH2 in aerobic glycolysis of prostate cancer through miR-181b/HK2 axis.
Tao T; Chen M; Jiang R; Guan H; Huang Y; Su H; Hu Q; Han X; Xiao J
Oncol Rep; 2017 Mar; 37(3):1430-1436. PubMed ID: 28184935
[TBL] [Abstract][Full Text] [Related]
5. EZH2 blockade by RNA interference inhibits growth of ovarian cancer by facilitating re-expression of p21(waf1/cip1) and by inhibiting mutant p53.
Seward S; Semaan A; Qazi AM; Gruzdyn OV; Chamala S; Bryant CC; Kumar S; Cameron D; Sethi S; Ali-Fehmi R; Morris R; Bouwman DL; Munkarah AR; Weaver DW; Gruber SA; Batchu RB
Cancer Lett; 2013 Aug; 336(1):53-60. PubMed ID: 23603558
[TBL] [Abstract][Full Text] [Related]
6. SETD2 Restricts Prostate Cancer Metastasis by Integrating EZH2 and AMPK Signaling Pathways.
Yuan H; Han Y; Wang X; Li N; Liu Q; Yin Y; Wang H; Pan L; Li L; Song K; Qiu T; Pan Q; Chen Q; Zhang G; Zang Y; Tan M; Zhang J; Li Q; Wang X; Jiang J; Qin J
Cancer Cell; 2020 Sep; 38(3):350-365.e7. PubMed ID: 32619406
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growth.
Barsotti AM; Ryskin M; Zhong W; Zhang WG; Giannakou A; Loreth C; Diesl V; Follettie M; Golas J; Lee M; Nichols T; Fan C; Li G; Dann S; Fantin VR; Arndt K; Verhelle D; Rollins RA
Oncotarget; 2015 Feb; 6(5):2928-38. PubMed ID: 25671303
[TBL] [Abstract][Full Text] [Related]
8. p53 mutant-type in human prostate cancer cells determines the sensitivity to phenethyl isothiocyanate induced growth inhibition.
Aggarwal M; Saxena R; Asif N; Sinclair E; Tan J; Cruz I; Berry D; Kallakury B; Pham Q; Wang TTY; Chung FL
J Exp Clin Cancer Res; 2019 Jul; 38(1):307. PubMed ID: 31307507
[TBL] [Abstract][Full Text] [Related]
9. linc01088 promotes cell proliferation by scaffolding EZH2 and repressing p21 in human non-small cell lung cancer.
Liu JQ; Feng YH; Zeng S; Zhong MZ
Life Sci; 2020 Jan; 241():117134. PubMed ID: 31811854
[TBL] [Abstract][Full Text] [Related]
10. EZH2 Palmitoylation Mediated by ZDHHC5 in p53-Mutant Glioma Drives Malignant Development and Progression.
Chen X; Ma H; Wang Z; Zhang S; Yang H; Fang Z
Cancer Res; 2017 Sep; 77(18):4998-5010. PubMed ID: 28775165
[TBL] [Abstract][Full Text] [Related]
11. LncRNA LINC00673 inhibits p53 expression by interacting with EZH2 and DNMT1 in papillary thyroid carcinoma.
Meng XF; Zhao LY; Chu XF
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):2075-2083. PubMed ID: 30915752
[TBL] [Abstract][Full Text] [Related]
12. Gain-of-function p53 activates multiple signaling pathways to induce oncogenicity in lung cancer cells.
Vaughan CA; Singh S; Grossman SR; Windle B; Deb SP; Deb S
Mol Oncol; 2017 Jun; 11(6):696-711. PubMed ID: 28423230
[TBL] [Abstract][Full Text] [Related]
13. Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator.
Kim J; Lee Y; Lu X; Song B; Fong KW; Cao Q; Licht JD; Zhao JC; Yu J
Cell Rep; 2018 Dec; 25(10):2808-2820.e4. PubMed ID: 30517868
[TBL] [Abstract][Full Text] [Related]
14. LncRNA MEG3 inhibits the progression of prostate cancer by facilitating H3K27 trimethylation of EN2 through binding to EZH2.
Zhou Y; Yang H; Xia W; Cui L; Xu R; Lu H; Xue D; Tian Z; Ding T; Cao Y; Shi Q; He X
J Biochem; 2020 Mar; 167(3):295-301. PubMed ID: 31790140
[TBL] [Abstract][Full Text] [Related]
15. Long noncoding RNA UPK1A-AS1 indicates poor prognosis of hepatocellular carcinoma and promotes cell proliferation through interaction with EZH2.
Zhang DY; Sun QC; Zou XJ; Song Y; Li WW; Guo ZQ; Liu SS; Liu L; Wu DH
J Exp Clin Cancer Res; 2020 Oct; 39(1):229. PubMed ID: 33121524
[TBL] [Abstract][Full Text] [Related]
16. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer.
Ren G; Baritaki S; Marathe H; Feng J; Park S; Beach S; Bazeley PS; Beshir AB; Fenteany G; Mehra R; Daignault S; Al-Mulla F; Keller E; Bonavida B; de la Serna I; Yeung KC
Cancer Res; 2012 Jun; 72(12):3091-104. PubMed ID: 22505648
[TBL] [Abstract][Full Text] [Related]
17. Aberrant expression of EZH2 is associated with pathological findings and P53 alteration.
Shiogama S; Yoshiba S; Soga D; Motohashi H; Shintani S
Anticancer Res; 2013 Oct; 33(10):4309-17. PubMed ID: 24122997
[TBL] [Abstract][Full Text] [Related]
18. Focal adhesion kinase depletion reduces human hepatocellular carcinoma growth by repressing enhancer of zeste homolog 2.
Gnani D; Romito I; Artuso S; Chierici M; De Stefanis C; Panera N; Crudele A; Ceccarelli S; Carcarino E; D'Oria V; Porru M; Giorda E; Ferrari K; Miele L; Villa E; Balsano C; Pasini D; Furlanello C; Locatelli F; Nobili V; Rota R; Leonetti C; Alisi A
Cell Death Differ; 2017 May; 24(5):889-902. PubMed ID: 28338656
[TBL] [Abstract][Full Text] [Related]
19. BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype.
Gorodetska I; Lukiyanchuk V; Peitzsch C; Kozeretska I; Dubrovska A
Int J Cancer; 2019 Dec; 145(11):2974-2985. PubMed ID: 30968962
[TBL] [Abstract][Full Text] [Related]
20. Involvement of aberrantly activated HOTAIR/EZH2/miR-193a feedback loop in progression of prostate cancer.
Ling Z; Wang X; Tao T; Zhang L; Guan H; You Z; Lu K; Zhang G; Chen S; Wu J; Qian J; Liu H; Xu B; Chen M
J Exp Clin Cancer Res; 2017 Nov; 36(1):159. PubMed ID: 29141691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
